Human guinea pigs

When people put their bodies on the line in medical trials, can they be sure that scientists aren't cutting corners or preoccupied with stock prices?

Topics: Medicine, Books,

Human guinea pigs

On May 4, Ellen Roche, a healthy 24-year-old woman, inhaled a drug known as hexamethonium as part of an experiment at Johns Hopkins University designed to figure out what nerves are at work in asthma attacks. Although approved by the Food and Drug Administration for intravenous use in patients with high blood pressure until 1997, the drug was known to cause serious lung problems and was never approved for inhalation. But Roche, a laboratory worker and veteran medical research subject, didn’t know any of that, because the consent form the researcher, Dr. Alkis Togias, had her sign didn’t mention it.

It seems that Togias had missed the lung toxicity in his review of the literature and didn’t think the FDA’s pulling of the drug from the blood pressure market was important enough to mention in the consent form. (A simple search on Google in July turned up reports of the drug’s toxicity, and even if you can’t believe everything you read on the Web, the search results, if Togias ever sought them, would have given him cause to investigate further.) Neither he nor the internal committee charged with reviewing the study deemed it necessary to apply to the FDA for approval to use the drug in the trial. Even when the first volunteer to take hexamethonium developed a cough, Togias ignored the symptom and failed to report it to the internal review committee, saying that it was a respiratory infection going around campus.

On May 9, Roche was admitted to Hopkins’ intensive care unit, where she eventually needed a ventilator to breathe. She died on June 2.

“Hers was a truly noble act,” said a Hopkins statement reporting the findings of an internal review on July 16. By emphasizing Roche’s nobility, Hopkins implies that her death was akin to a casualty in a good war, a necessary loss of life on behalf of a greater cause. But in wars, soldiers know the risks. When information about other risks, like those attendant to Agent Orange, is suppressed, governments are rightly condemned. What makes Roche’s death an unconscionable tragedy is that had Hopkins followed the rules and Roche known the risks, her untimely death might not have occurred. Hopkins said it was taking full responsibility for Roche’s death, but it then laid the blame at Togias’ feet, criticizing his work and pledging to improve its research review procedures. It thought that would be enough to placate the feds.

It wasn’t. On July 19, the agency shut down all of the 2,400 or so federally funded human trials at the medical center. The response from Hopkins was a sputtering, angry press release that included the statement “We strongly believe that this action was taken in utter disregard of patients’ health and potentially of life.” To an outside observer, however, it would seem that it was Hopkins — in approving Togias’ protocol, including his utterly flawed consent form — and not the government that was guilty of such utter disregard. (The funding was reinstated, with provisions for strict supervision, on July 23.)

While still taking “responsibility,” Hopkins has also attempted to place the blame on the FDA’s shoulders, saying that the agency had, by not responding to December 2000 and April 2001 letters requesting approval of Hopkins’ recently revised research procedures, effectively bestowed that approval. That dishonest spin doctoring should be considered reprehensible in the face of the needless death of a healthy 24-year-old woman.

The self-righteous outrage evinced by Hopkins following the government’s action revealed an institutional arrogance that should give any potential human research subject pause. The list of institutions spanked by the federal government for bad research protocols includes Duke University, the University of Oklahoma, the University of Alabama at Birmingham and the University of Pennsylvania, where 18-year-old Jesse Gelsinger died in a gene therapy trial gone bad.

Important human trials have always included risks, but have also vastly improved our longevity and quality of life. So are they worth it to the participants, who often don’t benefit directly? And is there a cavalier attitude throughout medical research circles that makes the danger as great as recent events suggest? Those are questions that make Susan Quinn’s new book an important read. The book, aptly titled “Human Trials,” is a revealing inside look at the drama and frailty of our system of human experimentation. Quinn spent time with participants in trials of drugs for multiple sclerosis and rheumatoid arthritis, two autoimmune disorders in which the immune system mistakes the body’s own substances for foreign invaders.

For the most part, the risks taken by the patients in the trials in this book are minimal and fall well within the acceptable bounds of medical ethics. What’s not particularly reassuring are the ways in which industry attempts to minimize and offset its own risks.

The book’s main character, Harvard Medical School professor Howard Weiner, is an earnest, likable and ultimately very human doctor. Weiner’s journal, quoted liberally throughout the book, paints him as an occasionally stubborn pragmatist who will sidestep cumbersome rules to do what he thinks best for patients. He’s a respected academic, trained by leaders in the fields of immunology and neurology, where he has made important contributions, but markers of success seem to come more slowly to him than to some of his colleagues.

That may be due to his brand of optimistic contrarianism, which leads him to believe so strongly in a theory known as “oral tolerance,” upon which the drugs in these trials, Myloral and Colloral, are based, that he is heedless of scientific critics. The basic idea is that the immune system can become tolerant to those substances it’s destroying in autoimmune disorders if those same substances are introduced to the digestive system. The theory has been around for some time, and has support from some scientists, but no drugs based on it have ever been proven effective as a treatment for disease. Other researchers are skeptical, noting the theory’s similarities to homeopathy, whose effectiveness also remains unproven.

His slow progress in academia appears to drive Weiner into the arms of venture capitalists. They help him start a company, AutoImmune, that sets up an office in Lexington, Mass., and eventually goes public, with its shares now traded on the NASDAQ. From the start, there are conflicts everywhere. Corporate officials become nervous when Weiner brings a video camera to document meetings and presentations. Clinicians enrolling patients at their offices are put off by the contract research organization hired by AutoImmune to standardize the trials. (In her character development, Quinn occasionally missteps as a writer. References to things like “a lion getting a blow-job from a beautiful girl” and “Jew-boy” seem unnecessary.)

After going public, AutoImmune officials seem to become interested only in their stock price, and not in the efficacy of the drugs. The night before the rheumatoid arthritis trial results are to be announced, Weiner has a happy dream “that AutoImmune stock was trading at $32 — the trial had worked.” Significantly, he mentions the stock price first, not the successful trial on which that price is based. Citing time constraints, the company decides to skip Phase II trials of Myloral, an unorthodox step. (Phase I tests the safety of a new drug on a small group of healthy volunteers; Phase II tests the safety and efficacy of a new drug on a small group of sick patients; and Phase III tests safety and efficacy in a large group of patients.) And just like Abiocor, manufacturer of the artificial heart recently transplanted into a man in Louisville, Ky., it chooses secrecy over openness in describing its data.

Ultimately, Myloral and Colloral fail to outperform placebos in their trials. But just because a drug doesn’t work doesn’t mean you can’t sell it. According to a recent press release, the company has plans to market Colloral as an over-the-counter drug for rheumatoid arthritis, with FDA clearance. Quinn herself said that the failure of the trials made the story less of a “slam-dunk” narrative.

Still, that’s the important element that many overly optimistic researchers forget when creating human trials. Most of the drugs they test will fail, and given that, researchers must be supercareful when constructing trials. Quinn’s book shows that it’s easy to let things like stock prices distract you from issues of safety and efficacy. Some doctors criticized AutoImmune’s strict protocol, designed to produce the “cleanest” or most indisputable results possible, for leaving study participants without effective treatments for their illnesses while they were involved in the study.

Toward the end of the book, Henri Termeer, CEO of Genzyme and a member of AutoImmune’s board, argues that AutoImmune should have done its research in an academic center. “Biotechnology has been good for innovation,” he told Quinn, “but bad for investment.”

But who would say that academic centers treat their human subjects any better? It’s unlikely that Ellen Roche’s family would. Hopkins, in fact, has just become involved in a second imbroglio, this one involving one of its researchers conducting human trials in India. As more and more drugs are hyped earlier and earlier by journalists and investors, researchers need to be more and more careful how they conduct trials. Potential subjects need to be able to honestly assess the risks they’re taking when enrolling so they can be confident that the studies they are generous enough to participate in are as safe as possible.

Featured Slide Shows

  • Share on Twitter
  • Share on Facebook
  • 1 of 11
  • Close
  • Fullscreen
  • Thumbnails

    Ten spectacular graphic novels from 2014

    Beautiful Darkness by Fabien Vehlmann & Kerascoët
    Kerascoët's lovely, delicate pen-and-watercolor art -- all intricate botanicals, big eyes and flowing hair -- gives this fairy story a deceptively pretty finish. You find out quickly, however, that these are the heartless and heedless fairies of folk legend, not the sentimental sprites beloved by the Victorians and Disney fans. A host of tiny hominid creatures must learn to survive in the forest after fleeing their former home -- a little girl who lies dead in the woods. The main character, Aurora, tries to organize the group into a community, but most of her cohort is too capricious, lazy and selfish to participate for long. There's no real moral to this story, which is refreshing in itself, beyond the perpetual lessons that life is hard and you have to be careful whom you trust. Never has ugly truth been given a prettier face.

    Ten spectacular graphic novels from 2014

    Climate Changed: A Personal Journey Through the Science by Philippe Squarzoni
    Squarzoni is a French cartoonist who makes nonfiction graphic novels about contemporary issues and politics. While finishing up a book about France under Jacques Chirac, he realized that when it came to environmental policy, he didn't know what he was talking about. "Climate Changed" is the result of his efforts to understand what has been happening to the planet, a striking combination of memoir and data that ruminates on a notoriously elusive, difficult and even imponderable subject. Panels of talking heads dispensing information (or Squarzoni discussing the issues with his partner) are juxtaposed with detailed and meticulous yet lyrical scenes from the author's childhood, the countryside where he takes a holiday and a visit to New York. He uses his own unreachable past as a way to grasp the imminent transformation of the Earth. The result is both enlightening and unexpectedly moving.

    Ten spectacular graphic novels from 2014

    Here by Richard McGuire
    A six-page version of this innovative work by a regular contributor to the New Yorker first appeared in RAW magazine 25 years ago. Each two-page spread depicts a single place, sometimes occupied by a corner of a room, over the course of 4 billion years. The oldest image is a blur of pink and purple gases; others depict hazmat-suited explorers from 300 years in the future. Inset images show the changing decor and inhabitants of the house throughout its existence: family photos, quarrels, kids in Halloween costumes, a woman reading a book, a cat walking across the floor. The cumulative effect is serene and ravishing, an intimation of the immensity of time and the wonder embodied in the humblest things.

    Ten spectacular graphic novels from 2014

    Kill My Mother by Jules Feiffer
    The legendary Pulitzer Prize-winning cartoonist delivers his debut graphic novel at 85, a deliriously over-the-top blend of classic movie noir and melodrama that roams from chiaroscuro Bay City to Hollywood to a USO gig in the Pacific theater of World War II. There's a burnt-out drunk of a private eye, but the story is soon commandeered by a multigenerational collection of ferocious women, including a mysterious chanteuse who never speaks, a radio comedy writer who makes a childhood friend the butt of a hit series and a ruthless dame intent on making her whiny coward of a husband into a star. There are disguises, musical numbers and plenty of gunfights, but the drawing is the main attraction. Nobody convey's bodies in motion more thrillingly than Feiffer, whether they're dancing, running or duking it out. The kid has promise.

    Ten spectacular graphic novels from 2014

    The Motherless Oven by Rob Davis
    This is a weird one, but in the nervy surreal way that word-playful novels like "A Clockwork Orange" or "Ulysses" are weird. The main character, a teenage schoolboy named Scarper Lee, lives in a world where it rains knives and people make their own parents, contraptions that can be anything from a tiny figurine stashable in a pocket to biomorphic boiler-like entities that seem to have escaped from Dr. Seuss' nightmares. Their homes are crammed with gadgets they call gods and instead of TV they watch a hulu-hoop-size wheel of repeating images that changes with the day of the week. They also know their own "death day," and Scarper's is coming up fast. Maybe that's why he runs off with the new girl at school, a real troublemaker, and the obscurely dysfunctional Castro, whose mother is a cageful of talking parakeets. A solid towline of teenage angst holds this manically inventive vision together, and proves that some graphic novels can rival the text-only kind at their own game.

    Ten spectacular graphic novels from 2014

    NOBROW 9: It's Oh So Quiet
    For each issue, the anthology magazine put out by this adventurous U.K.-based publisher of independent graphic design, illustration and comics gives 45 artists a four-color palette and a theme. In the ninth issue, the theme is silence, and the results are magnificent and full of surprises. The comics, each told in images only, range from atmospheric to trippy to jokey to melancholy to epic to creepy. But the two-page illustrations are even more powerful, even if it's not always easy to see how they pertain to the overall concept of silence. Well, except perhaps for the fact that so many of them left me utterly dumbstruck with visual delight.

    Ten spectacular graphic novels from 2014

    Over Easy by Mimi Pond
    When Pond was a broke art student in the 1970s, she took a job at a neighborhood breakfast spot in Oakland, a place with good food, splendid coffee and an endlessly entertaining crew of short-order cooks, waitresses, dishwashers and regular customers. This graphic memoir, influenced by the work of Pond's friend, Alison Bechdel, captures the funky ethos of the time, when hippies, punks and disco aficionados mingled in a Bay Area at the height of its eccentricity. The staff of the Imperial Cafe were forever swapping wisecracks and hopping in and out of each other's beds, which makes them more or less like every restaurant team in history. There's an intoxicating esprit de corps to a well-run everyday joint like the Imperial Cafe, and never has the delight in being part of it been more winningly portrayed.

    Ten spectacular graphic novels from 2014

    The Shadow Hero by Gene Luen Yang and Sonny Liew
    You don't have to be a superhero fan to be utterly charmed by Yang and Liew's revival of a little-known character created in the 1940s by the cartoonist Chu Hing. This version of the Green Turtle, however, is rich in characterization, comedy and luscious period detail from the Chinatown of "San Incendio" (a ringer for San Francisco). Hank, son of a mild-mannered grocer, would like to follow in his father's footsteps, but his restless mother (the book's best character and drawn with masterful nuance by Liew) has other ideas after her thrilling encounter with a superhero. Yang's story effortlessly folds pathos into humor without stooping to either slapstick or cheap "darkness." This is that rare tribute that far surpasses the thing it celebrates.

    Ten spectacular graphic novels from 2014

    Shoplifter by Michael Cho
    Corinna Park, former English major, works, unhappily, in a Toronto advertising agency. When the dissatisfaction of the past five years begins to oppress her, she lets off steam by pilfering magazines from a local convenience store. Cho's moody character study is as much about city life as it is about Corinna. He depicts her falling asleep in front of the TV in her condo, brooding on the subway, roaming the crowded streets after a budding romance goes awry. Like a great short story, this is a simple tale of a young woman figuring out how to get her life back, but if feels as if it contains so much of contemporary existence -- its comforts, its loneliness, its self-deceptions -- suspended in wintery amber.

    Ten spectacular graphic novels from 2014

    Through the Woods by Emily Carroll
    This collection of archetypal horror, fairy and ghost stories, all about young girls, comes lushly decked in Carroll's inky black, snowy white and blood-scarlet art. A young bride hears her predecessor's bones singing from under the floorboards, two friends make the mistake of pretending to summon the spirits of the dead, a family of orphaned siblings disappears one by one into the winter nights. Carroll's color-saturated images can be jagged, ornate and gruesome, but she also knows how to chill with absence, shadows and a single staring eye. Literary readers who cherish the work of Kelly Link or the late Angela Carter's collection, "The Bloody Chamber," will adore the violent beauty on these pages.

  • Recent Slide Shows



Comment Preview

Your name will appear as username ( settings | log out )

You may use these HTML tags and attributes: <a href=""> <b> <em> <strong> <i> <blockquote>